Cephalon’s Fentanyl Drugs Join Class-Wide REMS; Shared System Still To Come
By
Derrick Gingery / Email the Author / “The Pink Sheet” Jul. 25, 2011, Vol. 73, No. 30
Drug Safety / Word Count: 988 / Article # 00110725019
Executive Summary
Cephalon’s Actiq and Fentora will undergo increased distribution restrictions after joining FDA’s class-wide REMS for transmucosal fentanyl drugs, but a shared system, one of the main tenets of the risk management plan, is still under development.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.